STL-101

STL-101 is an investigational **microbiome-derived neuroprotective small molecule** developed by **Stellate Therapeutics**. It is described by the company and related publication sources as a **chemically synthesized form of queuine**, a bacterial-derived hypermodified nucleobase that is salvaged by humans and incorporated into transfer RNA biology. Preclinical work suggests STL-101 may support translational fidelity and cellular proteostasis, with reported reductions in **alpha-synuclein aggregation** and **tau hyperphosphorylation** in neuronal models, positioning it as a potential disease-modifying therapy for neurodegenerative disorders. Publicly disclosed development appears focused on **Parkinson's disease** and **Alzheimer's disease**, with evidence of preclinical neuroprotection but no clearly identified late-stage clinical program under the STL-101 name.

Other names

synthetic queuinechemically synthesized queuinesynthesized queuine